public electronic shop greece
Public Citizen Names Two Groups For Whom Fosamax Has No Benefit of Therapy
Bone-strengthening medication Fosamax became one of the bestselling drugs in the United States and the rest of North America due to the millions of people taking this drug for osteoporosis. Although this bisphosphonate works in wonder against osteoporosis, it also carries undesirable effects, including a risk for osteonecrosis of the jaw. But before anything else, let’s take deeper look on this severe dental condition called osteonecrosis of the jaw.
Not so long ago, the food and drug Administration (FDA) addressed the issue about doctors less cautiously ordering bisphosphonates to their patients. Furthermore, consumer activist Public Citizen cited two groups who are not getting any benefits from Fosamax medications. These groups may only be putting themselves at risk of developing this jaw bone disease unnecessarily.
Osteonecrosis of the jaw, which is commonly known as ONJ or “dead jaw,” pertains a dental condition where a portion of the jawbone protrudes above the gums. This bone tissue does not receive enough blood supply, which eventually causes its death or necrosis. The terms “Bis-Phossy Jaw” and BON are invented by scientists who refer to ONJ as having been brought by the use of bisphosphonates, such as Fosamax.
During the first stage of ONJ, patient seems asymptomatic until the later stages when one could experience pain, swelling and redness usually associated with gum infections. ONJ is often diagnosed by the presence of exposed bone tissue, which more often lasts for more than eight weeks. Additionally, the condition may be worsened by dental procedures like tooth extraction.
In most cases, ONJ is treated non-surgically with antimicrobial rinses, systemic antibiotics, systemic or topical antifungal medications and pain reliever. In later stages, treatment might require surgical debridement or resection in conjunction with other nonsurgical treatment. It is best for anyone to let the dentist know if he or she is on bisphosphonate therapy before any dental procedures or even minor surgeries are performed.
In July 2005, Merck changed the label of Fosamax regarding ONJ risk as ordered by FDA. Nonetheless, several long-term Fosamax patronizers claimed that Merck lacked proper disclosure of the said risk causing them to agonize such side effect and other backlash. Several individuals who believed to have harmed by the drug are now filing a Fosamax lawsuit against the manufacturer of the drug.
Peter Zinovieff and Electronic music Studios
We thank you taking the time to visit our website
and hope that we were able to assist you in your search for the information that you are looking for.
We do realize that with many articles written, it is possible
and even likely that you will find errors along the way.
We would appreciate you using the "contact us" page to let us know if you come across any mistakes
in our articles or if you simply have some ideas for articles that you would like to see in the future.
Thanks again for taking the time to visit,
we hope you have enjoyed it and hope that you will visit us again someday very soon.
